by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Slides:



Advertisements
Similar presentations
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Advertisements

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas by Yoshiyasu Aoki, Giovanna Tosato, Yoshihiro Nambu, Aikichi.
How I treat elderly patients with myeloma
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
by Alexander Röth, Andreas Hüttmann, Russell P
Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients by Oluwagbemiga O. Ayoola, Rahman A.
by Sabah Sallah, and Jim Y. Wan
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,
How I treat refractory CLL
Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.
Volume 2(Supplement 1):63-66
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Activity of eltrombopag in severe aplastic anemia
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma by Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung.
Where there’s a will, there’s a way: establishing hematopoietic stem cell transplantation in Myanmar by Aye Aye Gyi, Rai Mra, Htun Lwin Nyein, Thida Aung,
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,
Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.
Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.
by J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A
Volume 2(Supplement 1):8-10
Michael J. Hochman, BS, Yinxi Yu, BS, Steven P. Wolf, MS, Greg P
by Kaiwen Chen, Matthew P. Cheng, Sarah P
Volume 2(Supplement 1):1-3
Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
Plasma biomarker concentrations between study groups.
by Christine L. Kempton, and Amanda B. Payne
by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A
Volume 2(Supplement 1):46-49
Ontogeny of platelet function
Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,
by Elizabeth C. Neil, and Lisa M. DeAngelis
by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther
MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods by Mikhail Roshal, Juan A. Flores-Montero,
Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.
Bridge to transplant following Bv+Bs regimen.
by Wendy Lim, Sara K. Vesely, and James N. George
Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.
Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.
Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Volume 2(Supplement 1):39-41
Vitamin K for reversal of excessive vitamin K antagonist anticoagulation: a systematic review and meta-analysis by Rasha Khatib, Maja Ludwikowska, Daniel.
by David Deambrosis, Su Han Lum, Ryan M
CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking by Juliet N. Barker, Jane Kempenich, Joanne.
Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis by Juliet N. Barker, Kirsten Boughan, Parastoo.
High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation by Koichi Miyamura, Takuya Yamashita,
Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.
Resistance mechanism for ibrutinib in marginal zone lymphoma
by Catherine Lai, Vishal Ranpura, Colin Wu, Matthew J. Olnes, Ankur R
The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.
A binding relationship with thrombin
Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations by Ami B. Patel, Erin M. Pettijohn,
Full Uncapped Doses Of Chemotherapy In Non-Hodgkin's Lymphoma Patients With a High Body Surface Area Are Well Tolerated With No Increase In Toxicity, and.
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Volume 2(Supplement 1):4-7
Cold agglutinin disease
Presentation transcript:

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc Disparities in place of death for patients with hematological malignancies, 1999 to 2015 by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc BloodAdv Volume 3(3):333-338 February 12, 2019 © 2019 by The American Society of Hematology

Fumiko Chino et al. Blood Adv 2019;3:333-338 © 2019 by The American Society of Hematology

Trends in place of death resulting from HMs (1999-2015). Trends in place of death resulting from HMs (1999-2015). Location by primary site (A) and by race and ethnicity (B). Fumiko Chino et al. Blood Adv 2019;3:333-338 © 2019 by The American Society of Hematology